Determinants of aortic sclerosis progression: Implications regarding impairment of nitric oxide signalling and potential therapeutics

European Heart Journal

Volumn 33, Issue 19, 2012, Pages

  Sverdlov, Aaron L ^a   Ngo, Doan T M ^a   Chan, Wai P A ^a   Chirkov, Yuliy Y ^a   Gersh, Bernard J ^b   McNeil, John J ^c   Horowitz, John D ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b Mayo Clinic College of Medicine   (United States)

^c MONASH UNIVERSITY   (Australia)

Author keywords

ACE inhibitors angiotensin receptor blockers; Ageing; Aortic valve sclerosis calcification; Endothelial function; Inflammation; Nitric oxide

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; C REACTIVE PROTEIN; CALCIFEDIOL; CALCIUM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LIPID; NITRIC OXIDE;

ADULT; AGED; AORTA ATHEROSCLEROSIS; AORTA VALVE STENOSIS; AORTIC VALVE BACKSCATTER; ARTERIAL STIFFNESS; ARTICLE; CORONARY RISK; DISEASE COURSE; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; THROMBOCYTE; ULTRASOUND;

AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; AORTIC VALVE; AORTIC VALVE STENOSIS; BIOLOGICAL MARKERS; DISEASE PROGRESSION; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; HUMANS; MALE; MIDDLE AGED; NITRIC OXIDE; SCLEROSIS;

EID: 84867312149     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehs171     Document Type: Article

References (54)

1. Iung B, Baron G, Butchart EG, Delahaye F, Gohlke-Barwolf C, Levang OW, Tornos P, Vanoverschelde JL, Vermeer F, Boersma E, Ravaud P, Vahanian A. A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. Eur Heart J 2003;24:1231-1243. (Pubitemid 36834640)
2. Lindroos M, Kupari M, Heikkila J, Tilvis R. Prevalence of aortic valve abnormalities in the elderly: an echocardiographic study of a random population sample. J Am Coll Cardiol 1993;21:1220-1225. (Pubitemid 23106200)
3. Freeman RV, Otto CM. Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies. Circulation 2005;111:3316-3326. (Pubitemid 40875006)
4. Otto CM, Lind BK, Kitzman DW, Gersh BJ, Siscovick DS. Association of aorticvalve sclerosis with cardiovascular mortality and morbidity in the elderly. N Engl J Med 1999;341:142-147. (Pubitemid 29325741)
5. Stewart BF, Siscovick D, Lind BK, Gardin JM, Gottdiener JS, Smith VE, Kitzman DW, Otto CM. Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J Am Coll Cardiol 1997;29:630-634. (Pubitemid 27116107)
6. Aronow WS, Ahn C, Shirani J, Kronzon I. Comparison of frequency of new coronary events in older subjects with and without valvular aortic sclerosis. Am J Cardiol 1999;83:599-600, A598.
7. Ngo DT, Sverdlov AL, Willoughby SR, Nightingale AK, Chirkov YY, McNeil JJ, Horowitz JD. Determinants of occurrence of aortic sclerosis in an aging population. JACC Cardiovasc Imaging 2009;2:919-927.
8. El-Hamamsy I, Balachandran K, Yacoub MH, Stevens LM, Sarathchandra P, Taylor PM, Yoganathan AP, Chester AH. Endothelium-dependent regulation of the mechanical properties of aortic valve cusps. J Am Coll Cardiol 2009;53: 1448-1455.
9. Kennedy JA, Hua X, Mishra K, Murphy GA, Rosenkranz AC, Horowitz JD. Inhibition of calcifying nodule formation in cultured porcine aortic valve cells by nitric oxide donors. Eur J Pharmacol 2009;602:28-35.
10. Bodegard J, Skretteberg PT, Gjesdal K, Pyorala K, Kjeldsen SE, Liestol K, Erikssen G, Erikssen J. Low-grade systolic murmurs in healthy middle-aged individuals: innocent or clinically significant? A 35-year follow-up study of 2014 Norwegian men. J Intern Med 2012;271:581-588.
11. Novaro GM, Katz R, Aviles RJ, Gottdiener JS, Cushman M, Psaty BM, Otto CM, Griffin BP. Clinical factors, but not C-reactive protein, predict progression of calcific aortic-valve disease: the Cardiovascular Health Study. J Am Coll Cardiol 2007; 50:1992-1998. (Pubitemid 350046337)
12. Ngo DT, Wuttke RD, Turner S, Marwick TH, Horowitz JD. Quantitative assessment of aortic sclerosis using ultrasonic backscatter. J Am Soc Echocardiogr 2004; 17:1123-1130. (Pubitemid 39388903)
13. Ngo DT, Heresztyn T, Mishra K, Marwick TH, Horowitz JD. Aortic stenosis is associated with elevated plasma levels of asymmetric dimethylarginine (ADMA). Nitric Oxide 2007;16:197-201. (Pubitemid 46149393)
14. Ueland T, Aukrust P, Dahl CP, Husebye T, Solberg OG, Tonnessen T, Aakhus S, Gullestad L. Osteoprotegerin levels predict mortality in patients with symptomatic aortic stenosis. J Intern Med 2011;270:452-460.
15. Ngo DT, Stafford I, Kelly DJ, Sverdlov AL, Wuttke RD, Weedon H, Nightingale AK, Rosenkranz AC, Smith MD, Chirkov YY, Kennedy JA, Horowitz JD. Vitamin D(2) supplementation induces the development of aortic stenosis in rabbits: interactions with endothelial function and thioredoxin-interacting protein. Eur J Pharmacol 2008;590:290-296.
16. Ngo DT, Stafford I, Sverdlov AL, Qi W, Wuttke RD, Zhang Y, Kelly DJ, Weedon H, Smith MD, Kennedy JA, Horowitz JD. Ramipril retards development of aortic valve stenosis in a rabbit model: mechanistic considerations. Br J Pharmacol 2011;162:722-732.
17. Roosens B, Droogmans S, Hostens J, Somja J, Delvenne E, Hernot S, Bala G, Degaillier C, Caveliers V, Delvenne P, Lahoutte T, Van Camp G, Cosyns B. Integrated backscatter for the in vivo quantification of supraphysiological vitamin D(3)-induced cardiovascular calcifications in rats. Cardiovasc Toxicol 2011;11: 244-252.
18. Gharacholou SM, Karon BL, Shub C, Pellikka PA. Aortic valve sclerosis and clinical outcomes: moving toward a definition. Am J Med 2011;124:103-110.
19. Nightingale AK, Horowitz JD. Aortic sclerosis: not an innocent murmur but a marker of increased cardiovascular risk. Heart 2005;91:1389-1393. (Pubitemid 41531805)
20. Grant JF, Chittleborough CR, Taylor AW, Dal Grande E, Wilson DH, Phillips PJ, Adams RJ, Cheek J, Price K, Gill T, Ruffin RE. The North West Adelaide Health Study: detailed methods and baseline segmentation of a cohort for selected chronic diseases. Epidemiol Perspect Innov 2006;3:4.
21. Cosmi JE, Kort S, Tunick PA, Rosenzweig BP, Freedberg RS, Katz ES, Applebaum RM, Kronzon I. The risk of the development of aortic stenosis in patients with 'benign' aortic valve thickening. Arch Intern Med 2002;162: 2345-2347. (Pubitemid 35332517)
22. Wilkinson IB, Cockcroft JR, Webb DJ. Pulse wave analysis and arterial stiffness. J Cardiovasc Pharmacol 1998;32 Suppl. 3:S33-S37. (Pubitemid 29019750)
23. Chirkov YY, Holmes AS, Willoughby SR, Stewart S, Horowitz JD. Association of aortic stenosis with platelet hyperaggregability and impaired responsiveness to nitric oxide. Am J Cardiol 2002;90:551-554.
24. Boger RH. The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. Cardiovasc Res 2003;59:824-833. (Pubitemid 38366238)
25. Heresztyn T, Worthley MI, Horowitz JD. Determination of L-arginine and NG, NG-and NG, NG′-dimethyl-L-arginine in plasma by liquid chromatography as AccQ-Fluor fluorescent derivatives. J Chromatogr B Analyt Technol Biomed Life Sci 2004;805:325-329. (Pubitemid 38596755)
26. McEniery CM, Wallace S, Mackenzie IS, McDonnell B, Yasmin, Newby DE, Cockcroft JR, Wilkinson IB. Endothelial function is associated with pulse pressure, pulse wave velocity, and augmentation index in healthy humans. Hypertension 2006;48:602-608. (Pubitemid 44843862)
27. Bland JM, Altman DG. Regression towards the mean. BMJ 1994;308:1499. (Pubitemid 24170175)
28. Wakabayashi K, Tsujino T, Naito Y, Ezumi A, Lee-Kawabata M, Nakao S, Goda A, Sakata Y, Yamamoto K, Daimon T, Masuyama T. Administration of angiotensinconverting enzyme inhibitors is associated with slow progression of mild aortic stenosis in Japanese patients. Heart Vessels 2011;26:252-257.
29. Rodriguez M, Martinez-Moreno JM, Rodriguez-Ortiz ME, Munoz-Castaneda JR, Almaden Y. Vitamin D and vascular calcification in chronic kidney disease. Kidney Blood Press Res 2011;34:261-268.
30. Iwata S, Walker MD, Di Tullio MR, Hyodo E, Jin Z, Liu R, Sacco RL, Homma S, Silverberg SJ. Aortic valve calcification in mild primary hyperparathyroidism. J Clin Endocrinol Metab 2012;97:132-137.
31. Bostrom KI, Rajamannan NM, Towler DA. The regulation of valvular and vascular sclerosis by osteogenic morphogens. Circ Res 2011;109:564-577.
32. Pompilio G, Rossoni G, Sala A, Polvani GL, Berti F, Dainese L, Porqueddu M, Biglioli P. Endothelial-dependent dynamic and antithrombotic properties of porcine aortic and pulmonary valves. Ann Thorac Surg 1998;65:986-992.
33. Ngo DT, Sverdlov AL, McNeil JJ, Horowitz JD. Correlates of arterial stiffness in an ageing population: role of asymmetric dimethylarginine. Pharmacol Res 2009;60: 503-507.
34. O'Brien KD, Reichenbach DD, Marcovina SM, Kuusisto J, Alpers CE, Otto CM. Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of 'degenerative' valvular aortic stenosis. Arterioscler Thromb Vasc Biol 1996;16: 523-532. (Pubitemid 26107723)
35. Otto CM, Kuusisto J, Reichenbach DD, Gown AM, O'Brien KD. Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies. Circulation 1994;90:844-853. (Pubitemid 24242754)
36. Zhou R, Tardivel A, Thorens B, Choi I, Tschopp J. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol 2010;11:136-140.
37. Skowasch D, Schrempf S, Preusse CJ, Likungu JA,Welz A, Luderitz B, Bauriedel G. Tissue resident C reactive protein in degenerative aortic valves: correlation with serum C reactive protein concentrations and modification by statins. Heart 2006; 92:495-498.
38. Miller JD, Chu Y, Brooks RM, Richenbacher WE, Pena-Silva R, Heistad DD. Dysregulation of antioxidant mechanisms contributes to increased oxidative stress in calcific aortic valvular stenosis in humans. J Am Coll Cardiol 2008;52:843-850.
39. Arishiro K, Hoshiga M, Negoro N, Jin D, Takai S, Miyazaki M, Ishihara T, Hanafusa T. Angiotensin receptor-1 blocker inhibits atherosclerotic changes and endothelial disruption of the aortic valve in hypercholesterolemic rabbits. J Am Coll Cardiol 2007;49:1482-1489. (Pubitemid 46482919)
40. Helske S, Lindstedt KA, Laine M, Mayranpaa M, Werkkala K, Lommi J, Turto H, Kupari M, Kovanen PT. Induction of local angiotensin II-producing systems in stenotic aortic valves. J Am Coll Cardiol 2004;44:1859-1866. (Pubitemid 39424087)
41. Nishimoto M, Takai S, Kim S, Jin D, Yuda A, Sakaguchi M, Yamada M, Sawada Y, Kondo K, Asada K, Iwao H, Sasaki S, Miyazaki M. Significance of chymasedependent angiotensin II-forming pathway in the development of vascular proliferation. Circulation 2001;104:1274-1279. (Pubitemid 32848117)
42. O'Brien KD, Shavelle DM, Caulfield MT, McDonald TO, Olin-Lewis K, Otto CM, Probstfield JL. Association of angiotensin-converting enzyme with low-density lipoprotein in aortic valvular lesions and in human plasma. Circulation 2002;106: 2224-2230. (Pubitemid 35222217)
43. Rosenhek R, Rader F, Loho N, Gabriel H, Heger M, Klaar U, Schemper M, Binder T, Maurer G, Baumgartner H. Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis. Circulation 2004;110: 1291-1295. (Pubitemid 39202347)
44. O'Brien KD, Probstfield JL, Caulfield MT, Nasir K, Takasu J, Shavelle DM, Wu AH, Zhao XQ, Budoff MJ. Angiotensin-converting enzyme inhibitors and change in aortic valve calcium. Arch Intern Med 2005;165:858-862. (Pubitemid 40563231)
45. Nadir MA, Wei L, Elder DH, Libianto R, Lim TK, Pauriah M, Pringle SD, Doney AD, Choy AM, Struthers AD, Lang CC. Impact of renin-angiotensin system blockade therapy on outcome in aortic stenosis. J Am Coll Cardiol 2011; 58:570-576.
46. Forstermann U. Oxidative stress in vascular disease: causes, defense mechanisms and potential therapies. Nat Clin Pract Cardiovasc Med 2008;5:338-349. (Pubitemid 351761708)
47. Chirkov YY, Holmes AS, Martelli JD, Horowitz JD. Effect of perindopril on platelet nitric oxide resistance in patients with chronic heart failure secondary to ischemic left ventricular dysfunction. Am J Cardiol 2004;93:1438-1440, A1410.
48. Willoughby SR, Rajendran S, Chan WP, Procter N, Leslie S, Liberts EA, Heresztyn T, Chirkov YY, Horowitz JD. Ramipril sensitizes platelets to nitric oxide: implications for therapy in high-risk patients. J Am Coll Cardiol 2012; in press.
49. Chan KL, Teo K, Dumesnil JG, Ni A, Tam J. Effect of lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial. Circulation 2010;121:306-314.
50. Cowell SJ, Newby DE, Prescott RJ, Bloomfield P, Reid J, Northridge DB, Boon NA. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 2005;352:2389-2397. (Pubitemid 40958435)
51. Rossebo AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, Gerdts E, Gohlke-Barwolf C, Holme I, Kesaniemi YA, Malbecq W, Nienaber CA, Ray S, Skjaerpe T, Wachtell K, Willenheimer R. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008;359:1343-1356.
52. Kawasaki M, Takatsu H, Noda T, Ito Y, Kunishima A, Arai M, Nishigaki K, Takemura G, Morita N, Minatoguchi S, Fujiwara H. Noninvasive quantitative tissue characterization and two-dimensional color-coded map of human atherosclerotic lesions using ultrasound integrated backscatter: comparison between histology and integrated backscatter images. J Am Coll Cardiol 2001;38:486-492. (Pubitemid 32721778)
53. Aronow WS, Ahn C, Kronzon I, Goldman ME. Association of coronary risk factors and use of statins with progression of mild valvular aortic stenosis in older persons. Am J Cardiol 2001;88:693-695. (Pubitemid 32831111)
54. Palta S, Pai AM, Gill KS, Pai RG. New insights into the progression of aortic stenosis: implications for secondary prevention. Circulation 2000;101:2497-2502. (Pubitemid 30366254)